Larimar Therapeutics, Inc. (LRMR)
Largest Insider Buys in Sector
LRMR Stock Price History Chart
LRMR Stock Performance
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Insider Activity of Larimar Therapeutics, Inc.
Over the last 12 months, insiders at Larimar Therapeutics, Inc. have bought $38.04M and sold $0 worth of Larimar Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Larimar Therapeutics, Inc. have bought $20.2M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Flynn James E (* Director by Deputization) — $1.42B. Hamilton Thomas Edward (director) — $999,996. THOMAS FRANK E (director) — $22,000.
The last purchase of 4,290,617 shares for transaction amount of $37.5M was made by Flynn James E (* Director by Deputization) on 2024‑02‑16.
List of Insider Buy and Sell Transactions, Larimar Therapeutics, Inc.
| 2024-02-16 | * Director by Deputization | 4.29M 6.6831% | $8.74 | $37.5M | -39.36% | |||
| 2024-02-16 | director | 57,208 0.0891% | $8.74 | $499,998 | -39.36% | |||
| 2024-02-14 | director | 2,000 0.0064% | $11.00 | $22,000 | -35.12% | |||
| 2023-12-07 | Chief Development Officer | 5,000 0.0119% | $3.73 | $18,662 | +104.96% | |||
| 2023-05-17 | President and CEO | 5,000 0.0114% | $3.71 | $18,525 | +8.67% | |||
| 2023-05-17 | Chief Financial Officer | 5,000 0.0115% | $3.73 | $18,632 | +8.67% | |||
| 2023-05-17 | director | 2,750 0.0063% | $3.73 | $10,258 | +8.67% | |||
| 2022-09-16 | 11.11M 49.2054% | $3.15 | $35M | +21.88% | ||||
| 2022-09-16 | director | 317,460 1.4059% | $3.15 | $999,999 | +21.88% | |||
| 2022-09-16 | President and CEO | 31,746 0.1406% | $3.15 | $100,000 | +21.88% | |||
| 2022-09-16 | Chief Financial Officer | 31,746 0.1406% | $3.15 | $100,000 | +21.88% | |||
| 2021-06-30 | 685,710 3.341% | $8.75 | $6M | -2.39% | ||||
| 2021-06-30 | director | 56,710 0.2763% | $8.75 | $496,213 | -2.39% | |||
| 2018-06-28 | Sale | See Remarks | 32,000 0.1034% | $10.00 | $320,000 | -47.50% | ||
| 2018-03-07 | Sale | See Remarks | 5,000 0.0194% | $10.00 | $50,000 | -8.25% | ||
| 2017-10-13 | director | 20,000 0.0343% | $1.95 | $38,988 | +75.12% | |||
| 2017-07-11 | Chief Medical Officer | 20,000 0.037% | $1.70 | $33,900 | +63.77% | |||
| 2017-05-11 | Chief Medical Officer | 19,600 0.0729% | $4.40 | $86,240 | -12.41% | |||
| 2017-05-10 | Chief Medical Officer | 400 0.0014% | $4.40 | $1,760 | -15.92% | |||
| 2016-12-19 | director | 20,000 0.0742% | $3.23 | $64,580 | +16.61% |
Insider Historical Profitability
| Flynn James E | * Director by Deputization | 6151406 9.6407% | $6.16 | 7 | 1 | <0.0001% |
| Hamilton Thomas Edward | director | 564798 0.8852% | $6.16 | 3 | 0 | +21.88% |
| Shankar Gopi | Chief Development Officer | 5000 0.0078% | $6.16 | 1 | 0 | |
| THOMAS FRANK E | director | 2000 0.0031% | $6.16 | 1 | 0 | |
| BEN-MAIMON CAROLE | President and CEO | 266829 0.4182% | $6.16 | 2 | 0 | +15.27% |
Institutional Investor Ownership
| Deerfield Management | $161.15M | 33.28 | 21.23M | +25.33% | +$32.57M | 0.39 | |
| RA Capital Management, L.P. | $45.88M | 9.48 | 6.05M | New | +$45.88M | 0.05 | |
| Janus Henderson | $30.46M | 6.3 | 4.02M | +52.25% | +$10.45M | 0.02 | |
| Blue Owl Capital Holdings Lp | $30.32M | 6.26 | 3.99M | +16.99% | +$4.4M | 2.54 | |
| Goldman Sachs | $25.94M | 5.36 | 3.42M | +2,452.98% | +$24.92M | 0.01 |